Timing of 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase inhibitor initiation and allograft vasculopathy progression and outcomes in heart transplant recipients

AIMS: Early studies from the 1990s have shown that statins improve survival and attenuate cardiac allograft vasculopathy (CAV). However, little contemporary data are available on the incremental benefit of statins with the current use of new‐generation immunosuppressive agents and the use of coronar...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:ESC Heart Fail
Autori principali: Asleh, Rabea, Briasoulis, Alexandros, Pereira, Naveen L., Boilson, Barry A., Edwards, Brooks S., Adigun, Rosalyn, Maltais, Simon, Daly, Richard C., Lerman, Amir, Kushwaha, Sudhir S.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2018
Soggetti:
Original Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6300821/
https://ncbi.nlm.nih.gov/pubmed/30019530
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12329
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi